SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending due to raised revenue guidance and strong Q3 earnings, sparking community discussion about the company's valuation and potential. Community members are actively discussing future price targets, potential acquisitions, and the impact of a recent strategic investment in TLPH. The company's success with DefenCath and expansion into new markets are key drivers of the current positive sentiment.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle ($CRCL) is trending due to its recent Q3 earnings report, which revealed strong revenue growth and increased USDC circulation, sparking mixed reactions in the community. While some investors see the dip as a buying opportunity given the company's solid performance and future potential, others are concerned about rising operating expenses and an expiring lockup period, leading to volatility.

Creative Media & Community Trust Corp. is a real estate investment trust that seeks to own, operate, and develop premier multifamily and creative office assets in vibrant and emerging communities throughout the United States. It operates through the following segments: Office, Hotel, and Lending. The Office segment consists of the rental of office space and other tenant services, including tenant reimbursements, parking, and storage space rental. The Hotel segment involves the operation of hotel properties. The Lending segment focuses on loans to small businesses. The company was founded in 1993 and is headquartered in Dallas, TX.

Creative Media & Community Trust

CMCT is trending due to news of a lending division sale, sparking interest in its micro float and potential for a short squeeze. While some traders express optimism for gains, others cite concerns over the company's debt, leading to discussions about risk management.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

News of Luckin Coffee's potential U.S. relisting is generating buzz, with community members speculating about the timeline and impact on the stock. Discussions also involve the company's expansion plans and potential competition with Starbucks. Despite some skepticism, many longs are optimistic about Luckin's growth and future prospects.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

JMIA is trending following recent earnings, with community members noting a widened loss but increased revenue. Discussions are centered on whether to buy the dip, with some expressing concerns about liquidity while others highlight positive growth and long-term profitability targets. Upcoming investor day is also a key point of focus for potential catalysts.

Leifras Co., Ltd. Engages in sport training, event and alliance & club activity support and healthcare activities. It provides services related to the organization and operations of sports schools and sports events for children and it also operate a robust social business sector, dispatching sports coaches to meet various community needs. The company was founded by Kiyotaka Ito on August 28, 2001 and is headquartered in Tokyo, Japan.

Leifras Co Ltd - ADR

LEIFRAS Co., Ltd. American Depositary Shares

$LFS is trending due to a massive surge, with community members pointing to a potential short squeeze and comparing it to other high-flying stocks. Discussions revolve around whether this run can continue and which stock could be the 'next LFS'. Some traders attribute the move to news regarding a contract in Nagoya, while others suspect a pump and dump.

On Holding AG engages in the development and distribution of sports products such as footwear, apparel, and accessories for high-performance running, outdoor, all-day activities, and tennis. It sells its products worldwide through independent retailers and global distributors, its own online presence, and its own stores. The company was founded by David Allemann, Olivier Bernhard, and Caspar Coppetti in January 2010 and is headquartered in Zurich, Switzerland.

On Holding AG - Ordinary Shares Class A

On Holding AG

On Holding (ONON) is trending due to positive investor sentiment following raised FY25 revenue growth outlook. The community is buzzing about the company's strong sales and potential for a short squeeze, while some debate its valuation and competition within the shoe market. The focus remains on the company's growth in Asia and overall execution.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as investors debate the stock's future following recent news and ahead of an upcoming earnings report, with some expressing concerns about cash burn and others highlighting potential catalysts like FAA certification progress and partnerships. Discussions include contrasting opinions on the company's prospects versus competitors and the impact of analyst ratings, while technical analysis and potential support/resistance levels are also being closely monitored. The community is focused on both short-term trading opportunities and the long-term vision for the eVTOL sector.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

Traders are closely watching AVXL as it approaches its EMA oral explanation, the last step before a decision on its Alzheimer's drug, blarcamesine. Community chatter revolves around the potential for conditional approval and how management addresses outstanding questions, especially concerning the drug's efficacy. Recent price action suggests heightened uncertainty, with some interpreting the need for an oral explanation as a sign of regulatory scrutiny, while others remain optimistic about blarcamesine's potential benefits and market position.

BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. It is also involved in the development of liquid biopsy tests for the early detection of biomarkers that are linked to diseases. It operates through the BioNexus Malaysia and Chemrex segments. The company was founded by Liew Choong-Chin on May 12, 2017 and is headquartered in Kuala Lumpur, Malaysia.

BioNexus Gene Lab Corp

BGLC is trending following strategic partnership news with Fidelion Diagnostics, sparking community discussion about its potential impact on Southeast Asia MRD commercialization. The community is weighing the low float against concerns of potential dilution from a recent shelf registration. Bullish investors are hoping for news regarding the company's Ethereum treasury.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$LCTX No, this all started because someone posted in $SANA about LCTX and I got a bunch of crap for asking honest questions about it. Sana isn&#39;t crap, you can look on reddit for some pretty good lengthy writeups (https://www.reddit.com/r/wallstreetbets/comments/1lkwgbi/sana_unequivocally_has_type_1_diabetes_cure_and/?utm_source=share&amp;utm_medium=web3x&amp;utm_name=web3xcss&amp;utm_term=1&amp;utm_content=share_button). They have about $170M cash right, runway for at least a year, they are reducing burn and prioritizing T1D. Current investors are committed to providing all capital needed to see T1D through (as stated by CEO). Their human data is mind-blowingly good and a massive competitive advantage, published in world&#39;s best journals. Their tech is TRANSPARENT. They have data and patents proving they have all the pieces working that are needed for a T1D cure. They will have a monopoly on this cure when it is approved and the market size will conservatively be $100B+. They are trading at a massive discount right now. You can whine about dilution all you want. It won&#39;t matter in the long run at the current price.

Adam

Cody

Jesse Kessler

reddit

$SANA unequivocally has Type 1 Diabetes cure and is massively undervalued. The case for $10B+ valuation and 10-20X+ returns.

$LCTX im not goading anyone. you came to our playground, not the other way around. not concerned about someone investing in crap like Sana to try to rip opregan apart

StockTwits Web

Lineage Cell Therapeutics Inc

Sana Biotechnology Inc

 No, this all started because someone posted in 

 about LCTX and I got a bunch of crap for asking honest questions about it. Sana isn't crap, you can look on reddit for some pretty good lengthy writeups (

). They have about $170M cash right, runway for at least a year, they are reducing burn and prioritizing T1D. Current investors are committed to providing all capital needed to see T1D through (as stated by CEO). Their human data is mind-blowingly good and a massive competitive advantage, published in world's best journals. Their tech is TRANSPARENT. They have data and patents proving they have all the pieces working that are needed for a T1D cure. They will have a monopoly on this cure when it is approved and the market size will conservatively be $100B+. They are trading at a massive discount right now. You can whine about dilution all you want. It won't matter in the long run at the current price.

LunarPixel87

@LunarPixel87 whine about dilution? its a preclinical asset. do you know how much money it will take and how many years to bring this to the market. in that time there could be a lot more competition. shit happens, all the time and its never that simple. how do u know it trades at a discount. if price goes down and they have to raise capital then your investment shrinks. in few years market cap could be 3b and price still be the same at $4. dont tell me about massive discount

 whine about dilution? its a preclinical asset. do you know how much money it will take and how many years to bring this to the market. in that time there could be a lot more competition. shit happens, all the time and its never that simple. how do u know it trades at a discount. if price goes down and they have to raise capital then your investment shrinks. in few years market cap could be 3b and price still be the same at $4. dont tell me about massive discount

@pThebee vertex paid over $2b for their t1d program that requires immunosuppression. It&#39;s an unmarketable therapy. I guarantee you they wish they could pay $2B for Sana. Sana is valued at $1B right now. They are immediately worth much more than $2B just as an acquistion target.

 vertex paid over $2b for their t1d program that requires immunosuppression. It's an unmarketable therapy. I guarantee you they wish they could pay $2B for Sana. Sana is valued at $1B right now. They are immediately worth much more than $2B just as an acquistion target.